Onconetix, Inc. (ONCO)
NASDAQ: ONCO · Real-Time Price · USD
3.450
-0.110 (-3.09%)
At close: Aug 1, 2025, 4:00 PM
3.340
-0.110 (-3.19%)
After-hours: Aug 1, 2025, 7:59 PM EDT
Zuora Revenue
Onconetix had revenue of $101.63K in the quarter ending March 31, 2025, a decrease of -85.49%. This brings the company's revenue in the last twelve months to $1.93M, up 153.70% year-over-year. In the year 2024, Onconetix had annual revenue of $2.52M with 4,217.31% growth.
Revenue (ttm)
$1.93M
Revenue Growth
+153.70%
P/S Ratio
0.15
Revenue / Employee
$385,063
Employees
5
Market Cap
1.80M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.52M | 2.47M | 4,217.31% |
Dec 31, 2023 | 58.47K | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ONCO News
- 17 days ago - Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement - GlobeNewsWire
- 6 weeks ago - Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel - GlobeNewsWire
- 7 weeks ago - Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders - GlobeNewsWire
- 2 months ago - Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq - GlobeNewsWire
- 2 months ago - Onco-Innovations Uplists to Cboe Canada - Business Wire
- 4 months ago - Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort - GlobeNewsWire
- 4 months ago - Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress - GlobeNewsWire
- 8 months ago - Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing - GlobeNewsWire